Is tocilizumab a hormonal drug? What is the difference?

Tocilizumab is not a hormone drug. It is a biological agent that targets cytokine receptors and is specifically a humanized monoclonal antibody drug. Its main mechanism of action is to inhibit the IL-6-mediated inflammatory signaling pathway by selectively blocking the interleukin-6 receptor (IL-6R). This mechanism of action is completely different from traditional hormone drugs, such as glucocorticoids (such as prednisone, dexamethasone), etc., which non-specifically regulate immune and inflammatory responses.

Hormonal drugs have broad-spectrum immunosuppressive effects, and long-term use may cause a series of systemic side effects such as increased blood sugar, osteoporosis, and water and sodium retention. As a targeted drug, tocilizumab has a more precise effect and mainly affects the IL-6 pathway without interfering with other hormone systems. Therefore, in the treatment of rheumatic diseases, tocilizumab is often used as a means to reduce or replace long-term steroid use, thereby helping patients reduce the risk of side effects caused by long-term use of glucocorticoids.

In addition, tocilizumab is a "targeted immunomodulatory drug" among biological agents, and is a modern immunobiological therapy for the treatment of rheumatism, along with TNF-α inhibitors and CD20 monoclonal antibodies. It is usually used as a back-line treatment when traditional treatments (such as methotrexate) are ineffective or poorly tolerated. It is especially suitable for patients with high activity and recurrent disease.

To summarize, tocilizumab is a targeted biological agent that precisely regulates the IL-6 signaling pathway and is not a hormonal drug. It is of great significance in the treatment of rheumatic diseases and is considered a safer and more controllable immune strategy as an alternative to long-term hormone therapy.

Reference materials:https://www.drugs.com/mtm/tocilizumab.html